New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
Novavax Appoints Rachel King to Board of Directors
-
Novavax Appoints Rachel King to Board of Directors
-
OvaScience and Millendo Therapeutics Provide Update on Merger Agreement and Financing
-
Simple Habit Wins 2018 Google Material Design Award for Best Experience
-
Form SC 13D PhaseBio Pharmaceuticals Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Internet of Things Market Growing? PsiKick Infographic Explores Shrinking Expectations
-
Winning Developer Solutions Announced in Inaugural Call for Code Global Challenge to Mitigate Effects of Natural Disasters
-
Spencer Trask & Co. Backed Venture Ultra Capital LLC Accepts New Capitalization
-
Form SC 13D Marker Therapeutics, Filed by: New Enterprise Associates 16, L.P.
-
Privacy Protection Platform WireWheel Closes $10 Million in Financing
-
Qadium Introduces First Product To Detect Malicious Network Traffic From Internet Edge
-
Infoworks Secures $25M in Series C Financing Led by NEA
-
Paladina Health Announces New Chief Medical Officer During Annual Provider Summit
-
PlacementTracker Publishes Q3 2018 Private Placement Market League Tables
-
SetPoint Medical Announces Data Supporting Continued Clinical Development of its Bioelectronic Device for Treatment of Rheumatoid Arthritis (RA)
-
Qpex Biopharma Announces Closing of $33 Million Series A Financing and Launch of Company to Address Worldwide Problem of Drug-Resistant Infections
-
Earlens Corporation Raises $87M Led by KCK Medical Technologies Group
-
OmniSci Demonstrates the Power of Extreme Analytics in the Escalating Fight Against the Opioid Crisis
-
Bison Capital Acquisition Corp. (BCAC) says Chairman has no relation or connection whatsoever with Chairman of Global Trend Intelligent Technologies
-
Bison Capital Acquisition Corp. Clarifies Information of Its Chairman and President
-
Bison Capital Acquisition Corp. Clarifies Information of Its Chairman and President
-
Veriflow Co-Founder and CTO Brighten Godfrey to Present at ONUG Fall 2018
-
CareLinx and Stride Partner to Bridge Health Insurance Gap for Professional Caregivers, the Fastest Growing Job Sector in the U.S.
-
Form 3 PhaseBio Pharmaceuticals For: Oct 17 Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
TapImmune And Marker Therapeutics Announce Successful Closing Of Previously Announced Merger And Financing
-
Timescale and Grafana Labs Integration Enhances Time-Series Data Exploration and Visualization for Organizations
-
SetPoint Medical Completes Enrollment in U.S. Pilot Study Evaluating Bioelectronic Device for Treatment of Rheumatoid Arthritis
-
Form SC 13D/A Nightstar Therapeutics Filed by: New Enterprise Associates 15, L.P.
-
Ledger Capital Partners with Opera Software to Grow its Blockchain Technology Initiative
-
NEA Promotes Paul Walker to General Partner
-
OmniSci (formerly MapD) Secures $55 Million in New Funding
-
MapD Rebrands to OmniSci
-
Stride Expands Leadership Team To Scale Its Benefits Platform for Gig and Independent Workers
-
NYC's Ascent Conference Announces Partner and Speaker Lineup
-
Topia's New Deferred Compensation Tool Delivers Fast, Accurate Cost Estimates for Global Moves
-
Silicon Valley Technology Executive Lily Shen Joins Transfix as Chief Operating Officer
-
Logix Federal Credit Union Selects Veriflow for Network Segmentation Verification
-
Robert Simonds' STX Adds Country Music Superstar Blake Shelton To UGLYDOLLS Cast
-
Galera Therapeutics Raises $150 Million for GC4419 Phase 3 Trial and Pre-Commercialization Activities in Lead Indication
-
Galera Therapeutics Raises $150 Million for GC4419 Phase 3 Trial and Pre-Commercialization Activities in Lead Indication
-
Form SC 13D Adaptimmune Therapeutics Filed by: New Enterprise Associates 14, L.P.
-
Roivant Launches Respivant Sciences to Develop Innovative Therapeutics for Respiratory Diseases
-
Industry Leader Jeffrey Wang Joins Veriflow as VP of Engineering
-
ViewLift Powers New Professional Fighters League Website
-
Robert Simonds' STX Adds Comedians Gabriel Iglesias & Wanda Sykes To All-Star UGLYDOLLS Cast
-
MapD Joins NVIDIA and Pure Storage to Unlock Analytics for a New Era of Intelligence
-
Timescale Announces TimescaleDB 1.0—Empowering Organizations to Leverage Time-Series Data to Analyze the Past, Understand the Present, and Predict the Future
-
StreamSets Brings DataOps to Hybrid Cloud Architectures
-
StreamSets Raises $35 Million in Series C Funding Round Led by Harmony Partners
-
New Study Reveals Talent-Mobility Disconnect That Fuels Employee Turnover

